Mirati Therapeutics announces updated data from ongoing clinical trial of sitravatinib
Mirati Therapeutics announced completed stage 1 safety and efficacy data from the Phase 1b clinical trial of single agent sitravatinib in patients with certain classes of oncogenic mutations. In the subset of evaluable NSCLC patients, 1/2 confirmed partial responses were observed with 2/2 patients. October 21, 2018